{"nctId":"NCT01582711","briefTitle":"Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT","startDateStruct":{"date":"2012-09"},"conditions":["Latent Tuberculosis Infection"],"count":1002,"armGroups":[{"label":"3HP Directly Observed Therapy (DOT)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: isoniazid and rifapentine"]},{"label":"3HP Self Administered Therapy (SAT)","type":"EXPERIMENTAL","interventionNames":["Behavioral: Self Administered Therapy (SAT)","Drug: isoniazid and rifapentine"]},{"label":"3HP SAT with SMS Reminders","type":"EXPERIMENTAL","interventionNames":["Behavioral: Self Administered Therapy (SAT)","Behavioral: SMS reminders","Drug: isoniazid and rifapentine"]}],"interventions":[{"name":"Self Administered Therapy (SAT)","otherNames":["SAT"]},{"name":"SMS reminders","otherNames":["SMS","phone text reminder"]},{"name":"isoniazid and rifapentine","otherNames":["PRIFTIN","RPT","P","INH","I"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and non-pregnant, non-nursing females\n* Age \\> 18 years\n* Weight \\> 45kg and considered appropriate to receive RPT 900mg and INH 900mg once weekly by the local site investigator\n* Willingness to provide signed informed consent.\n* Clinical indication for LTBI treatment such as: 1) persons with a positive tuberculin skin test (TST) as defined by CDC criteria or a positive interferon-gamma release assay (IGRA) defined per the manufacturers' guidelines AND one of the following: close contact to someone with culture confirmed TB, HIV infection, or \\> 2 cm2 of pulmonary parenchymal fibrosis on chest X-ray and no prior history of TB treatment; 2) TST or IGRA converters defined as a documented change from negative to positive within a two-year period; 3) Persons with any other clinical indication for LTBI treatment as locally defined including persons with a negative TST and/or IGRA (e.g. HIV-infected close contacts to an active pulmonary TB cases)\n\nExclusion Criteria:\n\n* Confirmed or suspected active TB\n* Contacts to a source case with known resistance to isoniazid or rifampin\n* Persons with a history (by written documentation or self-report) of ever receiving \\> 1 week of treatment for active or latent TB, regardless of whether the course was completed, because adherence may be different in people who previously took TB treatment\n* Persons who are not considered candidates for SAT by the local investigator\n* History of sensitivity or intolerance to isoniazid or rifamycins\n* Serum alanine aminotransferase (ALT, SGPT) \\> 5x upper limit of normal among persons in whom an ALT is determined\n* Persons with HIV-infection who 1) have a CD4 \\< 350 or 2) are currently receiving or planning to receive antiretroviral therapy in the first 120 days after study initiation (e.g., HIV-1 protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, CCR5 inhibitors or integrase inhibitors)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Completion Rate.","description":"To compare the treatment completion rates between participants randomized to DOT vs SAT without reminders and DOT versus SAT with weekly SMS reminders. Treatment completion is defined as taking at least 90% of the doses (11/12 doses of each drug) within 16 weeks of treatment initiation.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":null},{"groupId":"OG001","value":"248","spread":null},{"groupId":"OG002","value":"250","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders","description":"To compare the treatment completion rates between participants randomized to SAT without reminders versus SAT with weekly SMS reminders","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Who Completed Treatment Based on SOC vs SOC Plus MEMS","description":"The number and proportion of participants who adhered (completed treatment) based on pill count and self-report, considered to be standard of care (SOC) vs. the number of participants who completed treatment based on SOC plus MEMS cap.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":null},{"groupId":"OG001","value":"271","spread":null},{"groupId":"OG002","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":null},{"groupId":"OG001","value":"248","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]}]},{"type":"SECONDARY","title":"Availability and Acceptability","description":"To determine the availability and acceptability of using SMS reminders among all patients consenting to participate in the study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"229","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Drug-related Grade 3 or 4 Adverse Events or Death","description":"To determine the toxicity and tolerability by comparing the rates of any drug-related grade 3 or 4 adverse events or death between the DOT arm and the SAT arms (both combined and individually)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants Reason for Failure to Complete Treatment","description":"To compare the frequency, timing, and causes for failure to complete treatment between the DOT arm and the SAT arms (both combined and individually) including discontinuation due to:\n\n* non-adherence\n* any adverse event (AE)\n* a diagnosis of active TB\n* other reasons","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-specific Cost","description":"To collect patient-specific cost data related to the DOT and SAT arms","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361.50","spread":null},{"groupId":"OG001","value":"257.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Antituberculosis Drug Resistance","description":"To describe the pattern of antituberculosis drug resistance among Mycobacterium tuberculosis strains cultured from participants who develop active TB.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":337},"commonTop":["Other","Systemic Drug Reaction","Hepatitis","Thrombocytopenia","Neutropenia"]}}}